708 Side effects of BCG in the treatment of intermediate and high risk Ta T1 papillary carcinoma of the bladder: Results from EORTC GU Cancers Group randomized study 30962 comparing 1/3 dose vs full dose during 1 or 3 years
Brausi, M., Oddens, J., Sylvester, R., Colette, S., Gontero, P., Bono, A., Turkeri, L.Volume:
12
Language:
english
Journal:
European Urology Supplements
DOI:
10.1016/S1569-9056(13)61190-2
Date:
March, 2013
File:
PDF, 70 KB
english, 2013